Global Respiratory Device Market Research and Forecast, 2018-2023Posted by Orion Market Research on January 11th, 2019 “Smart inhaler to revitalize respiratory device market” Respiratory devices enable to supply respiratory gas mechanically to patients suffering from the impaired respiratory function. The respiratory gas is enhanced with oxygen; positive pressure is developed through the devices and the gas is conveyed into the lung. The global respiratory device market is expanding due to the prevalence of chronic respiratory diseases which includes Chronic Obstructive Pulmonary Disease (COPD), asthma and many more. in case of controlled respiration, ventilator assumes respiration effort with preset respiratory pressures in patients, while in assisted respiration the respiratory device reinforces spontaneous breathing. The modern respiratory devices adjust inhalations and exhalations automatically according to the patient’s requirements. The respiratory devices are available in the market in multiple versions such as long-term respiratory devices for intensive care, emergency respiratory devices for rescue application, and mobile home respiratory devices. Technological advancement The technological advancement in the respiratory device is boosting the global respiratory device market. The devices are designed with ergonomic features and enable to reduce impaired respiratory functions. While controlling respiratory devices, it detects at the early stage of patient's inhalation phase via flow trigger, through which the device assists spontaneous breath with preset overpressure, and enables in managing patient's respiratory efforts. In advanced respiratory devices, the spontaneous breathing effort and respiratory activity are monitored through highly sensitive thermal mass flow sensor or by the high dynamic differential pressure sensor. Additionally, set respiratory pressure and tidal volume is administered to be monitored exactly in respiratory devices to ensure safe functioning of the device. First Sensor is a sensor-based company which offers a technological platform to develop products such as chips and sensors. The company sensor solution for respiratory devices enables to provides sensitive and rapid thermal mass flow sensors. The device uses sensors to monitor technique and enable in detecting errors in time duration and technique of inhalation. Browse full report at https://www.omrglobal.com/industry-reports/respiratory-device-market/ The respiratory specialists from across the globe descend on Paris for the 2018 edition of the European Respiratory Society’s (ERS) International Congress. The Paris Expo Porte de Versailles will be hosting about 20,000 people from Europe, to enhance respiratory medicine and technology. The conference enables innovators to offer a glimpse of future respiratory device design, which enables patients in managing conditions such as COPD and asthma. According to the World Health Organization (WHO) in 2016, the prevalence of 251 million cases of COPD was seen globally and it is estimated that about 3.17 million deaths are caused due to COPD. The EU-funded multi-institutional research project, MyAirCoach, started testing at the end of 2016 at the University of Manchester and Imperial College London and Leiden University in the Netherlands. The project enables to contribute to the requirements of new asthma management approaches. The researchers develop data analysis and modeling software that enables patients and doctors to analyze through collected data. The MyAirCoach is based on MEDrecord platform where ergonomic and compact sensor gathers information from the inhaler and sends via smartphone to MEDrecord for analysis. The MyAirCoach mobile application is designed to increase awareness among patients of asthma and enables to improve inhaler techniques. A poor inhaler technique may not be associated to provide patients’ outcome, therefore technological advancement is necessary to improvise and boost global respiratory device market. The improper asthma inhaler devices may be associated with uncontrolled asthma; inadequate inhaler technique reduces drug deposition to the lungs, which lead to poor disease control and increase emergency hospital admissions. The emergence of smart inhalers represents massive development, through the use of Bluetooth technology to monitor inhaler usage. The smart inhalers integrated with monitoring devices record time of every dose of the patient via smartphone. In November 2017, Express Scripts entered in a partnership with Propeller Health that provides digital Bluetooth devices for patients with COPD or asthma. The partnership with Propeller Health enables to offer a digital solution to Express Scripts members using inhaler sensors and mobile app to manage respiratory diseases. The Propeller Health’s digital devices enable in remote monitoring of Express Scripts’ Pulmonary Care Value Program (PCV), that merged by specialized pulmonary pharmacist clinical support and patient association to improve patient care through reducing healthcare costs. The Propeller digital sensor is integrated into an inhaler that utilizes Bluetooth technology and synchronized via smartphone. The company launched the smart inhaler in early 2018, in Express Scripts' PVC Program. The partnership enables to reduce health costs by leveraging digital tools such as application and sensors. Propeller Health is known as "digital therapeutics," as they use technology to replace traditional medicines. In December 2018, Jerusalem-based Teva Pharmaceuticals’ sensor-packed, the app-connected digital inhaler is approved a from US FDA. The inhaler by small numbers will be available in 2019, through healthcare system pilot partnerships, with a full national launch planned for 2020. The Teva’s ProAir Digihaler will be used to prevent and treat bronchospasm, reversible obstructive airway diseases such as asthma or COPD. The inhaler will be detecting and measuring every use, transfers recorded information via Bluetooth-connected mobile app. Through which patients can review inhaler use and can share the recorded data with their doctors. The significant FDA approval of ProAir Digihaler enables patients to track inhaler use and provide data for managing respiratory disease and it is the major step in evolving technological innovations. Contact us Anurag Tiwari Like it? Share it! More by this author |